The two newest Alzheimer’s drugs, lecanemab and donanemab, work by attacking amyloid beta plaques, the sticky protein deposits that accumulate in the brains of people with Alzheimer’s disease. Both drugs showed meaningful slowing of cognitive decline in clinical trials. Both also come with a serious list of caveats: they must be infused intravenously in a clinical setting, they cost upward of $26,000 per year in the United States, they carry a significant risk of brain swelling and bleeding (a side effect called amyloid-related imaging abnormalities, or ARIA), and they are currently restricted to patients in the earliest stages of the disease.
Currently, most patients cannot access advanced Alzheimer’s treatments due to high cost, logistical barriers, side effects, and early-stage eligibility requirements.
Building on these challenges, a 2025 study published in Neurochemistry International by researchers at Kindai University in Japan presents a notable alternative. The drug candidate is inexpensive, has an established safety record in humans, is orally administered, and, in multiple animal models of Alzheimer’s disease, has been shown to reduce amyloid-beta plaques, decrease brain inflammation, and improve memory-related behaviors.
The compound under investigation is arginine, an amino acid commonly found in red meat, nuts, and nutritional supplements, but it is not currently used or recognized as a treatment for Alzheimer’s.
What Is Amyloid Beta and Why Does It Matter?
Understanding the central pathological event in Alzheimer’s disease is essential to contextualize the significance of this research.
Amyloid beta (Aβ) is a small protein fragment produced naturally in the brain throughout life. In healthy individuals, it is cleared continuously. In Alzheimer’s disease, Aβ fragments, particularly the 42-amino-acid form, Aβ42, misfold and clump into toxic oligomers, which then grow into fibrous plaques that accumulate between neurons. These plaques are a defining hallmark of the disease, and their formation is believed to trigger a cascade of downstream damage: neuroinflammation, loss of synaptic connections, and, eventually, the death of neurons responsible for memory and cognition.
Aβ plaques accumulate 15–20 years before Alzheimer’s symptoms appear. At diagnosis, plaques are often widespread. As a result, some researchers argue that the best interventions must be preventive, starting before memory issues and possibly decades before dementia.
An oral, safe, affordable, and disease-modifying therapy that can be initiated early is essential. Given that Alzheimer’s disease affects over 50 million individuals globally and lacks a cure, such an intervention may represent the only realistic path to achieving meaningful population-level impact. functions as a chemical chaperone, a molecule that stabilizes protein structure and prevents misfolding or aggregation. had previously shown that arginine suppresses the aggregation of misfolded polyglutamine proteins, which are responsible for a family of inherited neurodegenerative diseases called polyglutamine (PolyQ) disorders. In those diseases, just as in Alzheimer’s, the core pathological event is a protein that misfolds and clumps into toxic aggregates. Arginine, by stabilizing protein conformation, physically prevented clumping.
From there, the hypothesis was that if arginine can stabilize polyglutamine proteins, it may also stabilize amyloid beta and prevent its aggregation.
Three Layers of Evidence: Test Tubes, Flies, and Mice
In the test tube, the researchers incubated the Aβ42 peptide at body temperature and monitored its aggregation over time using a fluorescent dye that emits light upon binding to amyloid fibrils. Arginine suppressed Aβ42 aggregation in a dose-dependent manner at 1 mM, reducing aggregation by 80%. Electron microscopy confirmed that the amyloid fibrils that did form in the presence of arginine were structurally shorter and less organized than those formed without it.
In fruit flies (Drosophila) engineered to express a toxic form of Aβ42 in their eyes, the effects of arginine were visible and striking. These flies normally develop abnormal Aβ deposits in their larval eye tissue, and by the time they reach adulthood, their compound eyes shrink measurably due to Aβ-mediated toxicity. Flies fed arginine in their food showed significantly less Aβ deposition dose-dependently, and their eyes were substantially protected from shrinkage. Importantly, arginine did not reduce Aβ gene expression; it directly blocked aggregation, without interfering with upstream production.
In mice carrying human familial Alzheimer’s mutations (the AppNL-G-F knock-in model), arginine was delivered at a 6% concentration in drinking water starting at 5 weeks of age. Brain tissue analysis at six months of age showed visually apparent and quantitatively significant reductions in Aβ plaque coverage in both the cortex and hippocampus, the two brain regions most critically involved in memory. Critically, the number of so-called dense-core plaques, the most compact and mature form of Aβ deposits associated with the most advanced disease stages, was also significantly reduced at both 6 and 9 months of age. ELISA measurements confirmed that insoluble Aβ42 in brain tissue (the aggregated, hard-to-clear form) was substantially decreased in arginine-treated mice compared to untreated controls, while soluble Aβ42 remained unchanged, suggesting arginine specifically blocks the aggregation step.
The mice treated with arginine also showed measurable improvements in behavior. In the Y-maze test, a standard measure of working memory and spontaneous exploration, arginine-treated Alzheimer’s mice at nine months of age traveled significantly farther and entered significantly more maze arms than untreated Alzheimer’s mice, approaching the activity levels of healthy controls.
At the molecular level, arginine treatment reduced the expression of the inflammatory cytokine genes IL-1β, IL-6, and TNF in the brains of Alzheimer’s mice. This matters because neuroinflammation is one of the primary drivers of neuronal death downstream of Aβ accumulation. Suppressing amyloid plaques suppressed the inflammatory signals that follow.
Why This Is Not Just Another Supplement Story
This study merits distinction from the vast, largely unreliable landscape of supplement claims regarding brain health and dementia prevention. Archers are not claiming that taking arginine supplements will prevent or treat Alzheimer’s disease in humans. This is an animal study, and the authors are explicit about its limitations: the mouse model used does not replicate all aspects of human Alzheimer’s pathology (notably, it does not develop tau tangles or significant neuron loss); the animal models carry a specific genetic mutation not shared by most sporadic Alzheimer’s patients; and the dose used in mice is approximately twice the maximum oral arginine dose currently approved in Japan.
What the study rigorously establishes across three distinct experimental systems is a mechanistic proof of concept: arginine physically blocks Aβ42 aggregation, reduces plaque burden and neuroinflammation, and improves behavioral outcomes in animal models of Alzheimer’s disease. This is exactly the kind of preclinical foundation that justifies moving toward human clinical trials.
Arginine has been used clinically for decades. It is approved and administered to patients with urea cycle defects, mitochondrial disorders, including MELAS, and was recently tested in a phase 2 clinical trial for the neurological disease SCA6. In all of these contexts, its safety profile is well characterized. It crosses the blood-brain barrier. The researchers’ earlier work confirmed that oral arginine increases arginine concentration not just in the blood but in the brain itself.
The combination of established safety, oral bioavailability, brain penetration, and demonstrated anti-aggregation effects against Aβ42 positions arginine as a strong candidate for drug repositioning in Alzheimer’s disease. Specifically, it offers the potential for a safe, affordable, early-intervention therapy that could be administered years before clinical symptoms emerge.
The Broader Picture: One Drug, Many Diseases
The implications of this research extend beyond Alzheimer’s disease. Arginine has been shown in the scientific literature to suppress the aggregation of not just Aβ, but also alpha-synuclein (the protein involved in Parkinson’s disease), FUS (implicated in ALS), and polyglutamine proteins (responsible for Huntington’s disease and the spinocerebellar ataxias).
All of these diseases share a common mechanism involving protein misfolding, aggregation, and subsequent neuronal death. A molecule that broadly stabilizes protein conformation and acts as a molecular anti-aggregation agent could, in principle, have therapeutic relevance across this entire group of conditions.
The researchers frame arginine as a “drug repositioning” candidate, an existing, approved compound that could be rapidly advanced into clinical testing for a new indication, bypassing the multi-decade timeline typically required for novel drug development.
What Comes Next
For now, what this study provides is a compelling rationale for clinical investigation. The next step is a clinical trial in human Alzheimer’s patients testing whether oral arginine at safe doses can slow the pace of Aβ accumulation or cognitive decline in people at early or preclinical stages of the disease. Given arginine’s established safety in humans and its long clinical history, the barriers to initiating such a trial are lower than they would be for Alzheimer’s disease, which has proven highly resistant to therapeutic intervention. The challenges are not only biological but also economic and logistical, as the most effective treatments are accessible to only a limited subset of patients. An orally administered compound that is inexpensive to produce, has a long-standing safety record in humans, and is endogenously present represents a fundamentally different therapeutic opportunity. While it is premature to designate arginine as a treatment, current evidence supports considering it a serious candidate for further investigation.
References
Fujii, K., Takeuchi, T., Fujino, Y., Tanaka, N., Fujino, N., Takeda, A., Minakawa, E.N., & Nagai, Y. (2025). Oral administration of arginine suppresses Aβ pathology in animal models of Alzheimer’s disease. Neurochemistry International, 191, 106082. https://doi.org/10.1016/j.neuint.2025.106082